ASP7266, a novel antibody against human TSLPR, in the treatment of allergic disease

The inhibitory effect of ASP7266 on TSLP-induced chemokine (C-C motif) ligand (CCL) 17 mRNA expression was examined in human and monkey peripheral white blood cells. Intravenously administered ASP7266 at doses of 0.1 mg/kg and greater blocked CCL17 mRNA expression in peripheral white blood cells by...

Full description

Saved in:
Bibliographic Details
Published in:Journal of allergy and clinical immunology 2018-02, Vol.141 (2), p.AB13-AB13
Main Authors: Numazaki, Mako, Hanaoka, Kaori, Imamura, Emiko, Maeda, Masashi, Arai, Kazunori, Saito, Tetsu, Takamura, Fujiko, Suzuki, Hiroshi, Kubo, Satoshi, Furukawa, Shigetada
Format: Article
Language:English
Subjects:
Allergies
Blood
Lymphocytes
Medical treatment
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The inhibitory effect of ASP7266 on TSLP-induced chemokine (C-C motif) ligand (CCL) 17 mRNA expression was examined in human and monkey peripheral white blood cells. Intravenously administered ASP7266 at doses of 0.1 mg/kg and greater blocked CCL17 mRNA expression in peripheral white blood cells by at least 89% on day 9 after administration.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2017.12.042